Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML

Table 2

Treatment characteristics in the cohort of AML patients.

Treatment	(%)
High intensity treatment
Induction	68 (79.1)
AIDA PETHEMA	2 (2.3)
HIDAC	1 (1.1)
Low-intensity treatment
5 azacitidine	4 (4.7)
Others	4 (4.7)
Support treatment	7 (8.1)